Literature DB >> 29057235

PD-L1 as a biomarker in NSCLC: challenges and future directions.

Matthen Mathew1, Rachael A Safyan1, Catherine A Shu1.   

Abstract

Entities:  

Year:  2017        PMID： 29057235      PMCID： PMC5635251          DOI： 10.21037/atm.2017.08.04

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  25 in total

1.  Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.

Authors:  Achim Rittmeyer; Fabrice Barlesi; Daniel Waterkamp; Keunchil Park; Fortunato Ciardiello; Joachim von Pawel; Shirish M Gadgeel; Toyoaki Hida; Dariusz M Kowalski; Manuel Cobo Dols; Diego L Cortinovis; Joseph Leach; Jonathan Polikoff; Carlos Barrios; Fairooz Kabbinavar; Osvaldo Arén Frontera; Filippo De Marinis; Hande Turna; Jong-Seok Lee; Marcus Ballinger; Marcin Kowanetz; Pei He; Daniel S Chen; Alan Sandler; David R Gandara
Journal:  Lancet       Date:  2016-12-13       Impact factor: 79.321

2.  Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.

Authors:  Matthew D Hellmann; Naiyer A Rizvi; Jonathan W Goldman; Scott N Gettinger; Hossein Borghaei; Julie R Brahmer; Neal E Ready; David E Gerber; Laura Q Chow; Rosalyn A Juergens; Frances A Shepherd; Scott A Laurie; William J Geese; Shruti Agrawal; Tina C Young; Xuemei Li; Scott J Antonia
Journal:  Lancet Oncol       Date:  2016-12-05       Impact factor: 41.316

3.  Pembrolizumab for the treatment of non-small-cell lung cancer.

Authors:  Edward B Garon; Naiyer A Rizvi; Rina Hui; Natasha Leighl; Ani S Balmanoukian; Joseph Paul Eder; Amita Patnaik; Charu Aggarwal; Matthew Gubens; Leora Horn; Enric Carcereny; Myung-Ju Ahn; Enriqueta Felip; Jong-Seok Lee; Matthew D Hellmann; Omid Hamid; Jonathan W Goldman; Jean-Charles Soria; Marisa Dolled-Filhart; Ruth Z Rutledge; Jin Zhang; Jared K Lunceford; Reshma Rangwala; Gregory M Lubiniecki; Charlotte Roach; Kenneth Emancipator; Leena Gandhi
Journal:  N Engl J Med       Date:  2015-04-19       Impact factor: 91.245

4.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

Authors:  Martin Reck; Delvys Rodríguez-Abreu; Andrew G Robinson; Rina Hui; Tibor Csőszi; Andrea Fülöp; Maya Gottfried; Nir Peled; Ali Tafreshi; Sinead Cuffe; Mary O'Brien; Suman Rao; Katsuyuki Hotta; Melanie A Leiby; Gregory M Lubiniecki; Yue Shentu; Reshma Rangwala; Julie R Brahmer
Journal:  N Engl J Med       Date:  2016-10-08       Impact factor: 91.245

5.  Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer.

Authors:  Keiichi Ota; Koichi Azuma; Akihiko Kawahara; Satoshi Hattori; Eiji Iwama; Junko Tanizaki; Taishi Harada; Koichiro Matsumoto; Koichi Takayama; Shinzo Takamori; Masayoshi Kage; Tomoaki Hoshino; Yoichi Nakanishi; Isamu Okamoto
Journal:  Clin Cancer Res       Date:  2015-05-27       Impact factor: 12.531

Review 6.  Cancer genome landscapes.

Authors:  Bert Vogelstein; Nickolas Papadopoulos; Victor E Velculescu; Shibin Zhou; Luis A Diaz; Kenneth W Kinzler
Journal:  Science       Date:  2013-03-29       Impact factor: 47.728

7.  A Phase III Study of Durvalumab (MEDI4736) With or Without Tremelimumab for Previously Treated Patients With Advanced NSCLC: Rationale and Protocol Design of the ARCTIC Study.

Authors:  David Planchard; Takashi Yokoi; Michael J McCleod; Jürgen R Fischer; Young-Chul Kim; Marc Ballas; Kelvin Shi; Jean-Charles Soria
Journal:  Clin Lung Cancer       Date:  2016-03-17       Impact factor: 4.785

8.  Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial.

Authors:  Scott J Antonia; José A López-Martin; Johanna Bendell; Patrick A Ott; Matthew Taylor; Joseph Paul Eder; Dirk Jäger; M Catherine Pietanza; Dung T Le; Filippo de Braud; Michael A Morse; Paolo A Ascierto; Leora Horn; Asim Amin; Rathi N Pillai; Jeffry Evans; Ian Chau; Petri Bono; Akin Atmaca; Padmanee Sharma; Christopher T Harbison; Chen-Sheng Lin; Olaf Christensen; Emiliano Calvo
Journal:  Lancet Oncol       Date:  2016-06-04       Impact factor: 41.316

9.  EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.

Authors:  Justin F Gainor; Alice T Shaw; Lecia V Sequist; Xiujun Fu; Christopher G Azzoli; Zofia Piotrowska; Tiffany G Huynh; Ling Zhao; Linnea Fulton; Katherine R Schultz; Emily Howe; Anna F Farago; Ryan J Sullivan; James R Stone; Subba Digumarthy; Teresa Moran; Aaron N Hata; Yukako Yagi; Beow Y Yeap; Jeffrey A Engelman; Mari Mino-Kenudson
Journal:  Clin Cancer Res       Date:  2016-05-25       Impact factor: 12.531

10.  Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer.

Authors:  A S Mansfield; M C Aubry; J C Moser; S M Harrington; R S Dronca; S S Park; H Dong
Journal:  Ann Oncol       Date:  2016-08-08       Impact factor: 32.976
View more
  12 in total

Review 1.  Prognostic and Predictive Immunohistochemistry-Based Biomarkers in Cancer and Immunotherapy.

Authors:  Emanuelle M Rizk; Robyn D Gartrell; Luke W Barker; Camden L Esancy; Grace G Finkel; Darius D Bordbar; Yvonne M Saenger
Journal:  Hematol Oncol Clin North Am       Date:  2019-01-17       Impact factor: 3.722

2.  Expression of CD274 mRNA Measured by qRT-PCR Correlates With PD-L1 Immunohistochemistry in Gastric and Urothelial Carcinoma.

Authors:  So Young Kang; You Jeong Heo; Ghee Young Kwon; Kyoung-Mee Kim
Journal:  Front Oncol       Date:  2022-04-27       Impact factor: 5.738

3.  Immunological and nutritional predictive factors in patients receiving pembrolizumab for the first-line treatment of non-small cell lung cancer.

Authors:  Naoki Shijubou; Toshiyuki Sumi; Yuichi Yamada; Hisashi Nakata; Yuji Mori; Hirofumi Chiba
Journal:  J Cancer Res Clin Oncol       Date:  2022-04-09       Impact factor: 4.322

Review 4.  Emerging role of tumor cell plasticity in modifying therapeutic response.

Authors:  Siyuan Qin; Jingwen Jiang; Yi Lu; Edouard C Nice; Canhua Huang; Jian Zhang; Weifeng He
Journal:  Signal Transduct Target Ther       Date:  2020-10-07

5.  Deep Semi Supervised Generative Learning for Automated Tumor Proportion Scoring on NSCLC Tissue Needle Biopsies.

Authors:  Ansh Kapil; Armin Meier; Aleksandra Zuraw; Keith E Steele; Marlon C Rebelatto; Günter Schmidt; Nicolas Brieu
Journal:  Sci Rep       Date:  2018-11-26       Impact factor: 4.379

6.  Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors.

Authors:  Jeffrey M Conroy; Sarabjot Pabla; Mary K Nesline; Sean T Glenn; Antonios Papanicolau-Sengos; Blake Burgher; Jonathan Andreas; Vincent Giamo; Yirong Wang; Felicia L Lenzo; Wiam Bshara; Maya Khalil; Grace K Dy; Katherine G Madden; Keisuke Shirai; Konstantin Dragnev; Laura J Tafe; Jason Zhu; Matthew Labriola; Daniele Marin; Shannon J McCall; Jeffrey Clarke; Daniel J George; Tian Zhang; Matthew Zibelman; Pooja Ghatalia; Isabel Araujo-Fernandez; Luis de la Cruz-Merino; Arun Singavi; Ben George; Alexander C MacKinnon; Jonathan Thompson; Rajbir Singh; Robin Jacob; Deepa Kasuganti; Neel Shah; Roger Day; Lorenzo Galluzzi; Mark Gardner; Carl Morrison
Journal:  J Immunother Cancer       Date:  2019-01-24       Impact factor: 13.751

7.  Significant differences in T cell receptor repertoires in lung adenocarcinomas with and without epidermal growth factor receptor mutations.

Authors:  Eisaku Miyauchi; Tatsuo Matsuda; Kazuma Kiyotani; Siew-Kee Low; Yu-Wen Hsu; Yoko Tsukita; Masakazu Ichinose; Akira Sakurada; Yoshinori Okada; Ryoko Saito; Yusuke Nakamura
Journal:  Cancer Sci       Date:  2019-02-16       Impact factor: 6.716

Review 8.  Diagnosing Lung Cancer: The Complexities of Obtaining a Tissue Diagnosis in the Era of Minimally Invasive and Personalised Medicine.

Authors:  Anna E B McLean; David J Barnes; Lauren K Troy
Journal:  J Clin Med       Date:  2018-06-29       Impact factor: 4.241

Review 9.  Extracellular Vesicles as Biomarkers in Cancer Immunotherapy.

Authors:  Matthen Mathew; Mariam Zade; Nadia Mezghani; Romil Patel; Yu Wang; Fatemeh Momen-Heravi
Journal:  Cancers (Basel)       Date:  2020-09-30       Impact factor: 6.639

10.  The association between monocytic myeloid-derived suppressor cells levels and the anti-tumor efficacy of anti-PD-1 therapy in NSCLC patients.

Authors:  Jiuxing Feng; Shujing Chen; Shuangqi Li; Baitong Wu; Jiacheng Lu; Li Tan; Jiamin Li; Yuanlin Song; Guoming Shi; Yujiang Geno Shi; Jinjun Jiang
Journal:  Transl Oncol       Date:  2020-09-10       Impact factor: 4.243
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.